Bimekizumab treatment in patients with active axial spondyloarthritis: 52- week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies.

Details

Language :

English

ISSN :

00034967

Volume :

83

Issue :

2

Database :

Complementary Index

Journal :

Annals of the Rheumatic Diseases

Publication Type :

Academic Journal

Accession number :

175519140

Full Text :

https://doi.org/10.1136/ard-2023-224803